RESUMO
BACKGROUND: Digital inclusion and literacy facilitate access to health information and can contribute to self-care behaviors and informed decision-making. However, digital literacy is not an innate skill, but rather requires knowledge acquisition. OBJECTIVE: The present study aimed to develop, conduct, and measure the impact, on digital and health literacy, of a digital inclusion program aimed at community dwellers. METHODS: The program targeted the recruitment of people aged 55 and older that owned mobile devices with an internet connection in 3 cities in northern Portugal (Paredes de Coura, Guimarães, and Barcelos). The program was titled the Workshops for Online Technological Inclusion (OITO) project and, in each city, was promoted by the coordinator of municipal projects and organized as an in-person 8-workshop program, using mobile devices, smartphones, or tablets. A quasi-experimental design was used with a nonrandomized allocation of participants in each set of 8 workshops. Sociodemographic, health status, and mobile use information were collected at baseline. Digital and health literacy were measured via the Mobile Device Proficiency Questionnaire and the Health Literacy Scale questionnaires, respectively, at baseline (T1), program completion (T2), and a 1-month follow-up (T3). A self-reported measure of autonomy was evaluated at T1 and T2 using a visual scale. RESULTS: Most participants were women with primary schooling (up to 4 years) aged between 65 and 74 years and retired. The intervention had an 81% (97/120) recruitment rate, 53% (43/81) adherence, and 94% (67/71) satisfaction rate, with 81 participants completing the entire 8-workshop program. Most participants had owned their mobile device for more than one year (64/81, 79%), were frequent daily users (70/81, 86%), and had received their mobile device from someone else (33/64, 52%). Over 80% (71/81) of the participants who completed the intervention used Android smartphones. At baseline, participants had low baseline scores in digital literacy, but medium-high baseline scores in health literacy. They showed significant improvement in digital literacy at T2 and T3 compared to T1, but without a significant difference between T2 and T3, regardless of sex, age, or schooling. A significant improvement in self-reported autonomy was observed at T3 compared with baseline. Regarding health literacy, no significant differences were found at T2 or T3 compared to the baseline. CONCLUSIONS: The feasibility indicators showed that the OITO project methodology had a substantial rate of recruitment and satisfaction. Program participants had significant improvement in digital literacy after 8 workshops and maintained their score 1 month after completing the intervention. There was no significant change in health literacy during the project period.
RESUMO
Introdução: O acetato de leuprorrelina, substância ativa do medicamento Eligard®, é um análogo sintético não peptídeo do hormônio liberador do hormônio luteinizante (LHRH) que está bem estabelecido para o tratamento de primeira linha para pacientes com câncer de próstata avançado. Diversas opções de análogos LHRH estão disponíveis no Brasil, com diferentes formulações e periodicidade entre as aplicações. O Eligard® 45mg, de administração semestral, pode trazer vantagens clínicas e econômicas pela sua maior duração de efeito. Objetivo: Realizar uma avaliação econômica comparando diferentes apresentações de Eligard® e outros análogos LHRH no tratamento de pacientes com câncer de próstata avançado ou metastático no Brasil, sob as perspectivas do SUS, serviços públicos e saúde suplementar. Método: Modelos de Markov foram desenvolvidos para avaliar custos e desfechos em coortes de pacientes com câncer de próstata metastático, sem tratamento prévio, submetidos à terapia de privação androgênica e tratamentos subsequentes. Eligard® 45 mg, em sua forma de depósito semestral, foi colocado em perspectiva econômica com outras seis apresentações de análogos de LHRH disponíveis no mercado nacional. Resultados: O bloqueio androgênico, com qualquer um dos análogos LHRH avaliados, resultou em uma expectativa de vida média de 31,44 meses em todas as perspectivas analisadas...
